This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, we will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps your pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, we hope to find out if exenatide might also be helpful in gestational diabetes.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
10 microgram injected sub-cutaneously once
Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
glycemic control through insulin, glucose, c-peptide and glucagon assays
Time frame: duing testing days
TCF7L2 polymorphism
Time frame: During subject testing days
Exenatide Pharmacodynamics and Pharmacokinetics
Time frame: During testing days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.